| Name | Title | Contact Details |
|---|
Founded in 1950, Miami Children's Hospital is South Florida’s only licensed specialty hospital exclusively for children. The 289-bed hospital is renowned for excellence in all aspects of pediatric medicine with several specialty programs ranked among the best in the nation in 2010 by U.S.News & World Report. The hospital has also been designated an American Nurses Credentialing Center (ANCC) Magnet facility, the nursing profession’s most prestigious institutional honor and is home to the largest pediatric teaching program in the southeastern United States. With a medical staff of more than 650 physicians and over 2,000 employees, the hospital is renowned for excellence in all aspects of pediatric medical care from birth through adolescence, offering more than 40 pediatric specialties and subspecialties, and is home to Florida’s only free-standing pediatric trauma center.
Healthcare Integrated Technologies, Inc. is focused on developing effective, non-intrusive, resident monitoring technologies for senior living communities. Healthcare Integrated Technologies is headquartered in Knoxville, Tennessee.
Accudata Service is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CatalystRx is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Philadelphia, PA. To find more information about CatalystRx, please visit www.catalystrx.com
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.